1-6 of 6
Wael Harb
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results

Amitkumar Mehta, Wael Harb, Claire Xu, Yuan Meng, Linda Lee, Vivian Yuan, Zhengyi Wang, Pengfei Song, Joan Huaqiong Shen, Ajay K Gopal
Journal: Blood
Blood (2021) 138 (Supplement 1): 3542.
https://doi.org/10.1182/blood-2021-150606
Published: 2021
Journal Articles

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael Harb, Hui Yang, Dawn Pinchasik, Amy S. Kimball, James R. Berenson, MD
Journal: Blood
Blood (2016) 128 (22): 3325.
https://doi.org/10.1182/blood.V128.22.3325.3325
Published: 2016
Journal Articles

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Clinical Trials & Observations
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal, Jesus G. Berdeja
Journal: Blood
Blood (2016) 127 (26): 3360–3368.
https://doi.org/10.1182/blood-2015-11-683854
Published: 2016
Includes: Supplemental data
Journal Articles

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Wael Harb, Mansoor N. Saleh, MD, Kyriakos P Papadopoulos, MD, Feng Chai, MD, Maria Larmar, Giovanni Abbadessa, MD, Brian Schwartz, MD, Anthony Tolcher, MD
Journal: Blood
Blood (2015) 126 (23): 5116.
https://doi.org/10.1182/blood.V126.23.5116.5116
Published: 2015
Journal Articles

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)

James Berenson, MD, Alan Cartmell, Roger Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, MD, Morton Coleman, Robert A. Moss, MD, Robert M. Rifkin, Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, Jesus G. Berdeja, MD
Journal: Blood
Blood (2015) 126 (23): 373.
https://doi.org/10.1182/blood.V126.23.373.373
Published: 2015
Journal Articles

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Andrew M. Evens, DO, MSc, Julie M Vose, MD, MBA, Wael Harb, MD, Leo I. Gordon, MD, Robert Langdon, MD, Barbara Grant, MD, Julian Sprague, MD, PhD, Clara Plasencia, MS, Mint Sirisawad, MS, Jeanne Yue, MS, Ying Luan, PhD, Aaron Siek, BS, Lei Zhou, MD, Sriram Balasubramanian, PhD, Nancy L. Bartlett, MD
Journal: Blood
Blood (2012) 120 (21): 55.
https://doi.org/10.1182/blood.V120.21.55.55
Published: 2012